Sotorasib / Lumakras (Everest)

Description
Product introduction:
Sotorasib, also known as Sotororese (generic name: Sotorasib, brand name: Lumakras, code name: AMG510), is a covalent inhibitor of the KRAS G12C mutant. It binds to the KRAS G12C mutant protein, locking KRAS in its inactive state and thereby irreversibly inhibiting its activity. Clinical trial results showed that patients treated with Sotorasib achieved an overall response rate (ORR) of 36% (95% CI: 28–45), a disease control rate of 81% (95% CI: 73–87), and a median duration of response of 10 months. After more than 40 years of research on KRAS-mutant oncogenic proteins, it became the world’s first approved KRAS G12C inhibitor.

Indications:
For the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.

Dosage and administration:
Take 960 mg orally once daily at approximately the same time each day.
It may be taken with or without food.
Swallow tablets whole; do not chew, crush, or split them.

Adverse reactions:
The most common adverse reactions (≥20%) include diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities (≥25%) include decreased lymphocytes, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urine protein, and decreased sodium.

Precautions:
Hepatotoxicity: Monitor liver function tests every 3 weeks during the first 3 months of treatment, then monthly as clinically indicated. Based on severity, withhold, reduce the dose, or permanently discontinue LUMAKRAS.

Interstitial lung disease (ILD)/pneumonitis: Monitor for new or worsening pulmonary symptoms. For suspected ILD/pneumonitis, immediately withhold LUMAKRAS, and permanently discontinue if no other potential cause is identified.